Ashwani Verma
Stock Analyst at UBS
(2.27)
# 2,667
Out of 4,911 analysts
73
Total ratings
42.31%
Success rate
-0.2%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Neutral | $38 → $43 | $45.60 | -5.70% | 3 | Jul 11, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $152 → $174 | $132.14 | +31.68% | 9 | Jul 9, 2025 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $54 | $43.36 | +24.54% | 3 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $410 → $385 | $304.50 | +26.44% | 5 | Jun 30, 2025 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $16.54 | +39.06% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $26.13 | +60.73% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $70.20 | -13.11% | 1 | Jun 3, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $37.18 | +10.27% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $37.52 | +27.93% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $23.25 | -5.38% | 4 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.04 | +0.96% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $179 | $118.23 | +51.40% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $11.03 | +26.93% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $71.31 | +59.87% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $13.50 | +300.00% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $100.83 | +4.14% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $36.67 | -23.64% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $100.14 | -93.01% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.41 | +27.52% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.53 | +2,719.55% | 1 | Oct 11, 2022 |
Exelixis
Jul 11, 2025
Maintains: Neutral
Price Target: $38 → $43
Current: $45.60
Upside: -5.70%
Neurocrine Biosciences
Jul 9, 2025
Maintains: Buy
Price Target: $152 → $174
Current: $132.14
Upside: +31.68%
Legend Biotech
Jul 2, 2025
Maintains: Buy
Price Target: $60 → $54
Current: $43.36
Upside: +24.54%
United Therapeutics
Jun 30, 2025
Maintains: Buy
Price Target: $410 → $385
Current: $304.50
Upside: +26.44%
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $16.54
Upside: +39.06%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $26.13
Upside: +60.73%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $70.20
Upside: -13.11%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $37.18
Upside: +10.27%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $37.52
Upside: +27.93%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $23.25
Upside: -5.38%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.04
Upside: +0.96%
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $118.23
Upside: +51.40%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $11.03
Upside: +26.93%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $71.31
Upside: +59.87%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $13.50
Upside: +300.00%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $100.83
Upside: +4.14%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $36.67
Upside: -23.64%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $100.14
Upside: -93.01%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.41
Upside: +27.52%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.53
Upside: +2,719.55%